CureVac Jumps on EU Vaccine Talks Days After Sky-High IPO

This post was originally published on this site

Investing.com —   CureVac jumped 14% after the EU concluded a first round of talks for 225 million doses of a potential Covid-19 vaccine.

Curevac Bv (NASDAQ:CVAC) went public on Aug. 14, when it soared almost 250%. The company, backed by the Bill & Melinda Gates Foundation, is focused on using messenger RNA to treat diseases. The IPO raised more than $213 million.

The EU is also in talks with Johnson & Johnson (NYSE:JNJ) and Sanofi (NASDAQ:SNY) for their vaccines under development, and agreed last week an advanced purchase deal with AstraZeneca (NYSE:AZN) for at least 300 million doses of the shot it is developing with Oxford University, Reuters reported. CureVac said the talks included an option to supply 180 million additional doses.

Add Comment